The entrepreneur and creator of Microsoft highlighted the projects of the companies Pfizer and Moderna.
Tycoon Bill Gates pointed out that the first vaccines against the coronavirus could appear at the end of October, although he assured that most of the immunizations for the world will be in 2021.
“The only vaccine that, if everything goes perfectly, could request the emergency use license at the end of October would be that of Pfizer,” said the creator of Microsoft in an interview with the television channel CNBC.
However, the businessman also praised the projects of Moderna and the University of Oxford, which took up the tests together with the AstraZeneca laboratory.
Gates, who has invested more than $ 20 billion in vaccines with the Bill and Melinda Gates Foundation in recent years, believes that “Three or four of the vaccines will receive emergency approval in early 2021.”
“The good news is that the major vaccine companies said today that they will not even apply for an emergency use license until they have a proof of efficacy. We also have to follow all the safety steps so that people feel that they want to participate in the application of this vaccine, “he continued.
In an interview with Spiegel, Gates also questioned Donald Trump’s actions regarding the pandemic: “The response from the United States was much worse than it should have been. And the political leadership is fully responsible for this.”
Asked about the possibility that his foundation could finance part of the US fight against Covid, after the departure of the WHO, Gates was blunt: “Our foundation does not fill the gaps created by the United States government. It’s not our job. The last thing you want to do is help governments that act irresponsibly“.
Gates believes that the pandemic could end in late 2021 in the United States and even a year later for less developed countries.
In an interview with Bloomberg, he predicted: “For the rich world, we should be able to end this by the end of 2021, and for the world at large by the end of 2022.”
“The strongest answer will probably come from the protein subunit. With so many companies working on it, we can afford quite a few failures and still have something low-cost and long-lasting,” he concluded.